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ABSTRACT: Autosomal recessive LPIN1 mutations have been recently described as a novel cause of 
rhabdomyolysis in a few families. The purpose of the study was to evaluate the prevalence of 
LPIN1 mutations in patients exhibiting severe episodes of rhabdomyolysis in infancy. After 
exclusion of primary fatty acid oxidation disorders, LPIN1 coding sequence was determined in 
genomic DNA and cDNA. Among the 29 patients studied, 17 (59%) carried recessive nonsense or 
frameshift mutations, or a large scale intragenic deletion. In these 17 patients, episodes of 
rhabdomyolysis occurred at a mean age of 21 months. Secondary defect of mitochondrial fatty 
oxidation or respiratory chain was found in skeletal muscle of two patients. The intragenic 
deletion, c.2295-866_2410-30del, was identified in 8/17 patients (47%), all Caucasians, and 
occurred on the background of a common haplotype, suggesting a founder effect. This deleted 
human LPIN1 form was unable to complement ∆pah1 yeast for growth on glycerol, in contrast to 
normal LPIN1. Since more than 50% of our series harboured LPIN1 mutations, LPIN1 should be 
regarded as a major cause of severe myoglobinuria in early childhood. The high frequency of the 
intragenic LPIN1 deletion should provide a valuable criterion for fast diagnosis, prior to muscle 
biopsy.    ©2010 Wiley-Liss, Inc. 
KEY WORDS: Rhabdomyolysis, LPIN1, intragenic deletion, founder effect. 
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INTRODUCTION 
Myoglobinuria is a rare condition resulting from the destruction of skeletal muscle fibers (rhabdomyolysis). 
Hereditary myoglobinurias have been ascribed to mitochondrial fatty acid ß-oxidation defects (FAO), 
mitochondrial respiratory chain (RC) deficiency and inborn errors of glycogenolysis (Dubowitz and Fardeau, 
1995; Tein, 1999; Tonin, et al., 1990). Metabolic investigations include plasma carnitine and acylcarnitine 
profiles, urinary organic acids analysis and in vitro studies of FAO in fresh lymphocytes or in cultured fibroblasts. 
When the latter are normal, common practice recommends performing a skeletal muscle biopsy for histological 
and enzymatic studies. Despite these investigations, the disease mechanism remains unknown in at least half of 
the patients (Ohkuma, et al., 2009).  
Recently, LPIN1 mutations (MIM *605518) have been reported as a novel cause of rhabdomyolysis (Zeharia, et 
al., 2008). Lipin-1 is a 890 amino acid protein predominantly expressed in muscle and adipose tissue (Donkor, et 
al., 2007; Reue and Brindley, 2008; Reue and Zhang, 2008), initially identified by positional cloning in the fatty 
liver dystrophy mouse (fld) (Peterfy, et al., 2001). It exhibits a dual role, as a phosphatidate phosphatase 1 (PAP) 
for triacylglycerol and phospholipid biosynthesis (Donkor, et al., 2007; Han, et al., 2006), and as a transcriptional 
co-activator through its association with PPARα and PGC-1α to regulate the expression of genes encoding FAO 
and RC enzymes (Donkor, et al., 2008; Finck, et al., 2006; Reue and Zhang, 2008; Sugden, et al., 2010). 
Expression of LPIN1 is also required for adipocyte differenciation and function (Phan, et al., 2005). Lipin-1 
contains two highly conserved domains, a N-LIP domain (residues 1-114) of unknown function, and a C-LIP 
domain (residues 673-830) which contains the canonical DXDXT motif for PAP activity and the LXXIL motif for 
nuclear receptor binding (Reue and Brindley, 2008; Reue and Zhang, 2008). 
Studying a series of 29 cases of unexplained myoblobinuria, we found two LPIN1 mutations in 59% of the 
patients. Moreover, a prevalent intragenic deletion was observed, prompting to screen for this frequent LPIN1 
deletion prior to other tests in the investigation of myoglobinuric patients.  
MATERIALS AND METHODS. 
Patients. 
A total of 29 patients from 23 families (4 consanguineous families; 22 Eurocaucasians, 1 African, 5 Maghrebis 
and 1 Asian) were included in the study. Patients 1, 2 and 3 have been previously described (Zeharia, et al., 2008). 
Inclusion criteria were: i) episode(s) of rhabdomyolysis, ii) since early infancy (< 5 years), iii) plasma creatine 
phosphokinase (CK) levels above 10 000 UI/L during bouts of myoglobinuria.  
 
Metabolic investigations. 
Extensive metabolic work-up excluded primary FAO disorders, carnitine palmitoyl transferase 2 (CPT2) 
deficiency, glycogen storage diseases and dystrophinopathies. 
  In patients 1, 3 and 4, serum leptin and adiponectin levels were determined using a commercial 
radioimmunoassay kit (RIA, LINCO Research Inc., Saint Louis, MI, USA). 
Glucose metabolism was evaluated by HbA1c level and an oral glucose tolerance test (1.75 g/kg dextrose orally 
administrated, dosage of blood glucose and insulin at 0, 30, 60 and 120 min) in patients 1, 3 and 4.  
Body composition measurement was assessed by dual-absorptiometry (Hologic 4500W instrument) in patients 
3 and 4 (Ellis, et al., 2000). 
Phospholipids were assayed on muscle biopsies of patient 1 (previously described, (Zeharia, et al., 2008)) and 
patient 4 and on plasma samples of patients 1, 3, 4, by lipid extraction and HPLC-MS quantification, and 
compared to three control samples (Valianpour, et al., 2005). 
RC activities were measured spectrophotometrically in skeletal muscle and cultured skin fibroblasts (Rustin, et 
al., 1994). CPT2 activity was studied in skeletal muscle (Isackson, et al., 2006). 
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Molecular analyses.  
Informed consent was obtained from the patients using a form approved by the Hospital Necker ethics board 
committee. 
Genomic DNA and total RNA were obtained from peripheral blood leukocytes and/or cultured fibroblasts 
using standard procedures. cDNA synthesis was performed using High capacity cDNA reverse transcription kit 
(Applied Biosystems). 
The coding sequence of the LPIN1 gene (GenBank NM_145693.1) was entirely determined from cDNAs or 
genomic DNA. Sequencing reactions were performed with the Big Dye Terminator Cycle Sequencing kit v.3.1 and 
analyzed on an ABI3100 sequencer (Applied Biosystems). Sequence analyses were performed using Seqscape 
software v2.5 (Applied Biosystems).  
Parents’ genotype was established to determine the allelic transmission of the LPIN1 mutations.  
Mutations numbering is based on cDNA sequence, with +1 corresponding to the A of ATG translation initiation 
codon (codon 1) in the reference sequence. 
For the diagnosis of the intragenic deletion, a genomic DNA fragment extending from exon 17 to exon 20 was 
amplified by long range PCR, using specific primers (5’:  GCTGCTGAGTCCCAGCAGCCTCTTCTCTGC  3’; 
5’: GTGGTCGACTACTTCACAGAGTCTCACATA 3’) with 2.5 U LA-Takara DNA polymerase (TaKaRa Bio 
Inc. Japan) for 30 cycles (10 sec 94°C, 30 sec 65°C and 14 min at 68°C).  
The precise localization of the deletion breakpoints was established by sequencing a genomic DNA fragment 
amplified with the primers (5’: AAAGGTCTGGCACATCTTCTGTT  3' (intron  17) ; 5’: AATCCCATTTAGC 
CCACCGACTCAG 3' (intron 19)), with Taq DNA polymerase (Roche) for 35 cycles (30 sec 95°C, 30 sec 65°C 
and 2 min at 72°C).  
 Haplotype studies were performed in all patients carrying the genomic deletion and in their parents. We used 
the intragenic polymorphic markers D2S328, located in intron 16, and D2S168,  D2S2377, D2S2200, W437 and 
D2S2199 flanking the LPIN1 gene. 
The presence of sequences known to participate in genomic rearrangements was searched for using 
bioinformatic tools (http://www.repeatmasker.org) as well as analysis of splicing consensus motifs and splicing 
enhancers/silencers (http://spliceport.cs.umd.edu/, http://genes.mit.edu/burgelab/rescue-ese/, http://rulai.cshl.edu/ 
tools/ESE2/). 
The deleterious nature of the intragenic deletion on PAP activity was examined in a yeast complementation 
assay, using the ∆pah1 strain deleted for the yeast ortholog of the LPIN1 gene (Han, et al., 2006). LPIN1 cDNAs, 
normal and lacking exons 18 and 19, were obtained by RT-PCR and subcloned in the XhoI/BamHI sites of the 
BFG-I shuttle vector. The yeast ∆pah1 cells were transformed with the BFG-I plasmid encoding the normal human 
lipin-1 or the deleted human lipin-1 (lipin-1∆). After selection of yeast cells bearing plasmids, serial dilutions 
(1:10) of the cells were spotted onto YPD (complete medium, 2% glucose) and YPG (complete medium, 2% 
glycerol) and growth was scored after 3 days of incubation at 28 and 36°C.  
RESULTS.  
Molecular characterization of the patients. 
More than half of our myoglobinuric patients (17/29) were homozygous or compound heterozygous for LPIN1 
mutations or intragenic deletion (Table 1). These molecular abnormalities were confirmed both on cDNA and 
genomic DNA and not found in 250 control chromosomes.  
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Table 1. Clinical and molecular characterization of patients with LPIN1 mutations.  
 
*: patients previously described (Zeharia, et al., 2008).  CK = creatine phosphokinase. 
Patients of the same family share a fused box for mutation description. 
The patients 3, 5 and 9 had a sibling who died in the same condition (bout of rhabdomyolysis). 
 
Patient  Clinical presentation Mutation 
N°  Age 
S
e
x 
Ethnic 
origin 
Con 
san 
gui 
nity 
 
(CK: UI/L) 
Myolysis episodes 
(triggering event) Nucleotide Amino Acid 
1* 5y M Mauritania Yes 200 000 2 at 27 and 30m     (fever) 
c.192+2T>C 
c.192+2T>C 
p.Cys30LeufsX3                        
p.Cys30LeufsX3   
2* died 
at 6y F France No  
100-
150 000 
4 between 15m and 6y 
(fever) 
c.2401C>T  
c.2295-866_2410-30del 
p.Arg801X                     
p.Glu766_Ser838del 
3 *     10y F France No  120 000 3 between 18m and 10y (fever) 
c.1441+2T>C 
c.2295-866_2410-30del 
p.Asn417LysfsX22  
p.Glu766_Ser838del 
4 10y M France No  120 000 2 at 16m and 8y     (fever) 
c.377_380dup                            
c.2295-866_2410-30del 
p.Met128GlnfsX45 
p.Glu766_Ser838del 
5 18m M Belgium No 900 000 1 at 1y  c.2295-866_2410-30del 
 c.2295-866_2410-30del 
p.Glu766_Ser838del  
p.Glu766_Ser838del 
6 3y F France-Asia No 
300-
500 000  
2 at 2y and 2,5y                     
(fever) 
c.944C>G 
c.1162C>T 
p.Ser315X  
p.Arg388X 
7 
died 
at 
2.5y 
M Belgium No  57 000 1 at 2,5y                   (fever) 
8 died 
at 4y F Belgium No > 20 000 
1 at 4y                 
(fasting) 
 c.2295-866_2410-30del 
 c.2295-866_2410-30del 
p.Glu766_Ser838del  
p.Glu766_Ser838del 
9 died 
<1y M Egypt No > 20 000 
1 at 5m                          
(fasting) 
c.2513+1G>A                         
c.2513+1G>A 
p.Asp804ValfsX6     
p.Asp804ValfsX6 
10 died 
at 4y F England No 
10-      
450 000  
2 at 14m and 4y     
(fever) 
c.2295-866_2410-30del 
c.921delT 
p.Glu766_Ser838del 
p.Gln308ArgfsX36 
11 6y M North 
africa Yes 50 000 
1 at 5y                 
(general anesthesia) 
12 8y F North 
africa Yes 300 000 
1 at 2y                   
(fasting) 
c.1162C>T /  c.1162C>T p.Arg388X   p.Arg388X 
13 8y F Germany No 1 000 000 10 between 2 and 8y (fever) 
c.2295-866_2410-30del 
c.946_952del 
p.Glu766_Ser838del 
p.Asp316LeufsX26 
14 23y F France No > 100 000 
5 between 4 and 16 y 
(fever, fasting with local 
anaesthetic) 
15 15y M France No > 100 000 
7 between 4 and 16 y 
(fever, fasting with local 
anaesthetic) 
16 18y M France No > 100 000 
6 between 4 and 16 y 
(fever, fasting with local 
anaesthetic) 
c.1259delC                                 
c.2513+1G>A 
p.Pro420LeufsX39                                       
p.Asp804ValfsX6 
17 4y F Germany No 450 000 2 at 3y and 4 y c.2253_2254del                 
c.57C>A               
p.Leu752AlafsX17                          
p.Tyr19X 
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Thirteen different mutations were discovered scattered throughout the LPIN1 coding region, including 12 
nonsense mutations (either direct at residues 19, 315, 388, 801 or as a frameshift consequence) and 1 intragenic 
deletion (Figure 1). 9/12 nonsense mutations lead to a predicted protein totally lacking the C-LIP domain, and the 
3 remaining stop mutations are located within the C-LIP domain, but do not remove the DXDXT and LXXIL 
motifs. The last mutation, c.2295-866_2410-30del (p.Glu766_Ser838del), is an in-frame intragenic deletion, 
removing a large part (residues 766-838) of the C-LIP domain, but preserves both DXDXT and LXXIL motifs.  
 
 
 
 
Figure 1. Schematic diagram of the mutations reported on the lipin-1 protein. The highly conserved 
domains are shown as shaded boxes. Mutations (as amino acid changes) are indicated with vertical lines.  
 
 
Unexpectedly, this intragenic deletion was present in 8/17 patients, all Caucasians, who displayed an abnormal 
cDNA lacking exons 18 and 19. Long range PCR of their genomic DNA encompassing exons 17 to 20 generated 
an abnormal amplification product, approximately 2 kb shorter than that of controls. The breakpoints of the 
deletion were identical in all patients. The deletion was 1763 bp long and extended from intron 17 (nt +3377) to 
intron 18 (nt + 782, 30 bp upstream to exon 19), encompassing exon 18, but not exon 19.  
In silico analysis of splicing enhancers and branch-point within the deleted sequence did not bring clues to 
understand the absence of exon 19 at the cDNA level. Similarly, no repeated elements susceptible to mediate a 
recurrent chromosomal rearrangement were detected by sequence analysis in the vicinity of the breakpoints. A 
common minimal haplotype (markers D2S328, D2S2200 and D2S2199) segregated with the intragenic deletion in 
the 8 children. Because all these patients were of Caucasian origin, a founder effect is highly probable.  
   De novo mutations were not observed in our series as all 26 parents were heterozygous for one LPIN1 
mutation, except the symptomatic father of patients 11 and 12 who was homozygous due to his parent’s 
consanguinity. Unaffected children were homozygous or heterozygous for the wild type allele. 
 The functional consequences of the absence of exons 18 and 19 in the LPIN1 mRNA were examined in a yeast 
complementation assay as previously reported (Zeharia, et al., 2008). The ∆pah1 yeast strain was transformed by a 
plasmid encoding the human lipin-1 or its lipin-1∆ mutant. As described (Santos-Rosa, et al., 2005), the ∆pah1 
mutant strain grew more slowly than wild type cells (W303) at 28°C on glycerol and exhibited a temperature-
sensitive phenotype at 36°C on glucose and glycerol (Figure 2). This phenotype was complemented by expressing 
the human LPIN1 cDNA, as cells recovered a growth rate comparable to wild type cells at both 28 and 36°C. In 
contrast, ∆pah1 cells expressing the human lipin-1∆ mutant (figure 2) did not grow on glycerol at 28°C and 
glucose at 36°C indicating that the c.2295-866_2410-30del mutation of LPIN1 alters lipin-1 activity and is of 
functional significance. 
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Figure 2. Functional analysis of LPIN1 intragenic deletion by functional complementation of the 
yeast pah1 null mutant. Growth of the yeast wild type strain (W303) and ∆pah1 derivatives on either glucose 
(YPD) or glycerol (YPG) medium at 28 (left panels) and 36°C (right panels). ∆pah1 was transformed with the 
human wild-type LPIN1 (LPIN1) or mutant (lpin1∆) cDNAs. The five spots for each experiment correspond to 
decreasing dilutions of transformed yeast cells. 
 
 
Clinical investigations of patients with LPIN1 mutations. 
LPIN1 mutations were detected in patients of various ethnic origins: 12/22 Caucasian, 1/1 African, 1/1 Asian 
and 3/5 Maghrebi patients with a sex ratio M/F=0.89.  
Patients underwent their first bout of rhabdomyolysis before five years (median age = 21 months). Bouts were 
almost invariably precipitated by febrile illnesses and occasionally by anaesthesia or fasting (Table 1). The number 
of acute episodes ranged from 1 to 10 per patient. Five patients died during myoglobinuric bouts, and three 
siblings (not included in the study) died from similar episodes. One sibling of patient 10 died at 3 weeks of life 
from pneumonia. He also presented with cardiomegaly and hepatomegaly at the time of his death.  
Between episodes, all patients but one (patient 4) had normal physical examination including normal muscular 
testing. Their basal plasma CK levels were normal or subnormal as well. The oldest patient is now 23 years old. 
Patient 4 exhibited writing cramps and permanent myalgia increasing with effort and requiring wheel-chair. 
Abnormal muscular testing was noted. Another patient (patient 1) presented with recurrent episodes of severe 
atopic dermatitis.  
Most heterozygous parents (23/25) were asymptomatic. The two moderately symptomatic heterozygous carriers 
(cramps or moderate myalgias) harboured two different point mutations (mother of patient 2, c.2401C>T; and 
mother of patient 3, c.1441+2T>C). The healthy sister of patient 3, harbouring the LPIN1 intragenic deletion, 
reported exercise-induced muscle pain. The father of patients 11 and 12, homozygous for his children's mutation, 
suffered of numerous bouts of myoglobinuria. 
 
Metabolic investigations of patients with LPIN1 mutations. 
All patients including the oldest one had normal plasma levels of total, LDL and HDL cholesterol, 
triglycerides, and lactate. Electromyography and abdominal and heart ultrasounds were also normal; no liver 
steatosis was noted. Brain MRI was normal in all patients but one (patient 4) who had an arachnoid cyst. 
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Muscle histology was either normal or showed moderate abnormalities, including lipid inclusions, 
predominance of type I muscle fibers, atrophy of type II fibers and rarely subsarcolemmal aggregates of 
mitochondria with ragged-red fibers. Histochemical staining for cytochrome c oxidase (COX) activity and 
respiratory chain activities in skeletal muscle were normal in all patients but one : patient 2, whose muscle fiber 
staining revealed homogeneously weak COX activity (de Lonlay-Debeney, et al., 1999). 
Although a complete analysis of lipid metabolism could not be performed for every patient, partial data were 
available for some of them. The father of patients 11 and 12 had partial CPT2 deficiency in skeletal muscle (38 
mU/mg protein, controls 90 mU/mg protein), while CPT2 activity in fibroblasts and lymphocytes as well as CPT2 
gene sequencing were normal (data not shown).  
Analysis of phospholipids content in muscle tissues of patients 1 (Zeharia, et al., 2008) and 4 and in plasma of 
patients 1, 3 and 4 showed no difference in major phospholipid species compared to controls, including 
phosphatidic acid and lysophosphatidic acid (data not shown). 
Average weight percentiles and normal fat distribution were found in all patients, confirmed by dual-
absorptiometry in patients 3 and 4 (data not shown). Adiponectine and leptine plasma levels were normal in 
patients 1, 3 and 4, as well as oral glucose tolerance test and HbA1c level (data not shown). 
 
DISCUSSION  
Here, we report on a very high incidence of LPIN1 mutations in a large series of young patients with severe 
rhabdomyolysis. Because it accounted for 59% of cases in our study and 56% of tested families, LPIN1 mutations 
appear as the second cause of rhabdomyolysis of early-onset, after primary FAO defects as a whole. Moreover, 
since 8/17 mutated patients carried an intragenic deletion with identical breakpoints, on the background of a 
common haplotype, a founder effect of Caucasian origin is highly likely. The deleterious nature of this deletion, 
homozygous in some patients, was supported by yeast complementation assay. 
The outcome of the disease was severe, as five patients died during a myoglobinuric episode, as well as three 
siblings. Episodes of myoglobinuria were precipitated by febrile illnesses and in a few cases by fasting. Various 
inflammatory inducers including lipopolysaccharides, Zymosan and proinflammatory cytokines have been recently 
shown to repress LPIN1 expression, leading to decreased expression of PPARα, PPARγ and genes involved in 
energy metabolism (Feingold, et al., 2009; Lu, et al., 2008; Tsuchiya, et al., 2009). It is conceivable therefore that 
the acute-phase response induced by inflammation could cause dramatic alterations in lipid and lipoprotein 
metabolism (Gabay and Kushner, 1999; Kishimoto, et al., 1994) and eventually trigger episodes of myoglobinuria 
in lipin-1 deficient patients.  
 While lipodystrophy is a major feature in the natural Lpin1 mutant mouse strain fld (Peterfy, et al., 2001; Reue 
and Brindley, 2008; Reue, et al., 2000), neither insulin resistance, nor dyslipidemic signs were observed in our 
lipin-1 deficient children. The explanation of the different phenotypes presented by lipin-1 deficient mice and 
humans remains largely unknown, as well as the physiopathology of the muscular symptoms in man. Skeletal 
muscle is one of the tissues expressing the highest levels of lipin-1, which may explain why muscle is particularly 
affected by the LPIN1 mutations in human. Because of the multiple roles played by lipin-1, several mechanisms 
leading to rhabdomyolysis, alone or combined, may be considered.  
On the one hand, lipin-1 has an enzymatic PAP activity and is involved in glycerolipid biosynthesis. As it has 
been suggested (Zeharia, et al., 2008), lipin-1-related rhabdomyolysis could result from lyso-phosphatidate 
accumulation and the subsequent remodelling of membranes induced by phospholipid imbalances (Farooqui, et al., 
2000), as proposed in  Barth syndrome (Chicco and Sparagna, 2007; McKenzie, et al., 2006). The phospholipid 
content in skeletal muscle was abnormal in one previously described patient (Zeharia, et al., 2008) but not in two 
others, one already reported and another. Similarly, plasma phospholipid concentrations were in the normal range 
in three tested patients. The preliminary data available at this step do not support an important role of phospholipid 
imbalance alone as a trigger for massive rhabdomyolysis, also it could not be excluded. Moreover, there is 
growing evidence showing that triacylglycerol (TG) synthesis is coupled to fatty acid oxidation (Liu, et al., 2009). 
Fatty acids may have to be incorporated into TG and then turned over before they can be efficiently oxidized. 
Thus, low rates of TG synthesis resulting from mutations of LPIN1 could produce a defect in fatty acid oxidation. 
In this view, it should be noted that the ∆pah1 yeast complementation assay reflects PAP activity. Also bouts of 
rhabdomyolysis may result from the association of various functional defects linked to the PAP activity deficiency, 
but further studies are clearly required to determine how alterations in these pathways participate to the disease. 
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On the other hand, lipin-1 also plays a role of co-activator in PPARα and PGC-1α-mediated transcription, 
which stimulates the expression of genes related to mitochondrial energy pathways (Donkor, et al., 2008; Finck, et 
al., 2006; Higashida, et al., 2008). Besides, lipin-1 has been clearly demonstrated to act in exercise-induced 
adaptation and oxidative gene expression in muscle (Higashida, et al., 2008). Alteration of this co-activator activity 
could down-regulate simultaneously several metabolic pathways important for the energetic supply of muscle cells 
(Phan, et al., 2005). The isolated metabolic data currently available in our patients (abnormal oxidative 
phosphorylation activity, CPT2 activity defect) might be compatible with the hypothesis of an energy-dependent 
muscle disease, but need to be confirmed in more extensive studies. On this line, it should be noted that defective 
growth on glycerol medium of the ∆pah1 yeast strain suggests a global impairment of aerobic/oxidative 
metabolism, even though it does not assess lipin-1 transcriptional activity.  
Further investigations will help understand the links between deficiency of each of lipin-1 activities and the 
disease. 
 In conclusion, lipin-1 deficiency should be regarded as a major cause of severe myoglobinuria in early 
childhood. Since 59% of our cohort display deleterious LPIN1 mutations, it may prompt clinicians to include the 
screening for LPIN1 mutations at early stage of the metabolic work up of myoglobinurias, after exclusion of FAO 
defects, but certainly prior to muscle biopsy. The high frequency of the intragenic LPIN1 deletion in the Caucasian 
patients provides a valuable screening test to diagnose these patients, before sequencing the full LPIN1 sequence. 
Finally, we believe that metab lic investigations of severe rhabdomyolysis in young patients should include 
successively i) metabolic investigation of FAO, ii) research of the intragenic LPIN1 deletion in blood samples by 
long range PCR, iii) full coding sequence analysis of LPIN1 gene in blood, iv) only if all these results are normal, 
proceed to skeletal muscle biopsy. 
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